(krih-ZOH-tih-nib)
This page contains brief information about crizotinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Crizotinib is approved to treat:
- Anaplastic large cell lymphoma that is ALK positive and systemic. It is used in children aged 1 year and older and young adults whose cancer has relapsed (come back) or is refractory (does not respond to treatment).
- Inflammatory myofibroblastic tumor that is ALK positive. It is used in adults and children aged 1 year and older whose cancer is relapsed, refractory, or cannot be removed by surgery.
- Non-small cell lung cancer that is ALK positive or ROS1 positive and has spread to other parts of the body.
Crizotinib is also being studied in the treatment of other types of cancer.
More About Crizotinib
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Crizotinib – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Crizotinib – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
